Gossamer Bio Inc. (GOSS) Reports In-Line Q4 EPS

Gossamer Bio Inc. (NASDAQ: GOSS) reported Q4 EPS of ($0.74), in-line with the analyst estimate of ($0.74).

Cash, cash equivalents and marketable securities as of December 31, 2021, were $325.2 million. As a result, we currently expect cash, cash equivalents and marketable securities, and access to our debt facility will be sufficient to fund operating and capital expenditures into the second half of 2023.

For earnings history and earnings-related data on Gossamer Bio Inc. (GOSS) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth